Cargando…
A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors
Background Combinations of molecularly targeted agents may provide optimal anti-tumor activity and improve clinical outcomes for patients with advanced cancers. Selumetinib (AZD6244, ARRY-142886) is an oral, potent and highly selective, allosteric inhibitor of MEK1/2, a component of the RAS/RAF/MEK/...
Autores principales: | Infante, Jeffrey R., Cohen, Roger B., Kim, Kevin B., Burris, Howard A., Curt, Gregory, Emeribe, Ugochi, Clemett, Delyth, Tomkinson, Helen K., LoRusso, Patricia M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5613062/ https://www.ncbi.nlm.nih.gov/pubmed/28424891 http://dx.doi.org/10.1007/s10637-017-0459-7 |
Ejemplares similares
-
Erratum to: A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors
por: Infante, Jeffrey R., et al.
Publicado: (2017) -
A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors
por: LoRusso, Patricia M., et al.
Publicado: (2017) -
A first-in-human dose-escalation study of ME-143, a second generation NADH oxidase inhibitor, in patients with advanced solid tumors
por: Pant, Shubham, et al.
Publicado: (2013) -
A phase I dose-escalation study of TAK-733, an investigational oral MEK inhibitor, in patients with advanced solid tumors
por: Adjei, Alex A., et al.
Publicado: (2016) -
A phase Ib combination study of RO4929097, a gamma-secretase inhibitor, and temsirolimus in patients with advanced solid tumors
por: Diaz-Padilla, Ivan, et al.
Publicado: (2013)